Sellas Life Sciences Group Inc (SLS)

Oct 28, 2026

SELLAS Life Sciences Group (Nasdaq: SLS) announced that its pivotal Phase III REGAL trial for galinpepimut-S (GPS), an immunotherapy for acute myeloid leukemia (AML), has finally reached the 80th death milestone, triggering its final overall survival analysis. This achievement, nearly 10 months later than anticipated, has fueled speculation about GPS's survival benefit, with topline efficacy results expected in Q4 2026. The trial addresses a significant unmet need for AML patients in second complete remission who cannot undergo allogeneic stem cell transplantation.

Oct 28, 2026

SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares fell after the company announced its Phase 3 REGAL trial for an acute myeloid leukemia immunotherapy reached the critical 80-death milestone, triggering the final analysis. While this is a significant step, the results of whether the experimental immunotherapy, galinpepimut-S (GPS), is effective in prolonging patient life are still unknown and are expected later this quarter. The stock's current decline reflects the uncertainty surrounding these upcoming top-line findings.

Oct 28, 2026

SELLAS Life Sciences Group announced that its Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML) has reached its pre-specified 80th event (death), triggering the final analysis. The company will now proceed with database lock, unblinding, and statistical analysis, with preliminary topline primary endpoint results expected to be announced this quarter. This milestone marks a critical step towards evaluating GPS as a potential maintenance therapy for AML patients.

Oct 27, 2026

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 15,872,685 shares in SELLAS Life Sciences Group Inc., representing 7.9% of the company's outstanding common stock as of September 30, 2026. The asset manager holds sole voting power over 15,499,019 shares and sole dispositive power over all reported shares, with no shared authority. This update reflects BlackRock's significant stake in the life sciences company.